BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 111 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,452,220 | +14172.4% | 506,000 | -74.9% | 0.08% | -83.7% |
| Q2 2023 | $10,175 | +167.2% | 2,014,858 | 0.0% | 0.47% | +152.4% |
| Q1 2023 | $3,808 | -99.9% | 2,014,858 | 0.0% | 0.19% | -2.1% |
| Q4 2022 | $3,626,744 | +6.5% | 2,014,858 | 0.0% | 0.19% | 0.0% |
| Q3 2022 | $3,405,000 | -31.3% | 2,014,858 | 0.0% | 0.19% | -39.2% |
| Q2 2022 | $4,957,000 | -11.2% | 2,014,858 | 0.0% | 0.31% | +9.4% |
| Q1 2022 | $5,581,000 | -48.0% | 2,014,858 | 0.0% | 0.29% | -31.2% |
| Q4 2021 | $10,739,000 | -37.0% | 2,014,858 | 0.0% | 0.42% | -29.9% |
| Q3 2021 | $17,046,000 | -30.6% | 2,014,858 | 0.0% | 0.60% | -31.4% |
| Q2 2021 | $24,561,000 | -49.8% | 2,014,858 | 0.0% | 0.87% | -47.7% |
| Q1 2021 | $48,880,000 | -24.3% | 2,014,858 | 0.0% | 1.66% | -20.1% |
| Q4 2020 | $64,576,000 | +6.0% | 2,014,858 | 0.0% | 2.08% | -1.4% |
| Q3 2020 | $60,909,000 | -28.3% | 2,014,858 | 0.0% | 2.10% | -43.6% |
| Q2 2020 | $84,946,000 | +69.0% | 2,014,858 | 0.0% | 3.74% | +9.0% |
| Q1 2020 | $50,271,000 | – | 2,014,858 | – | 3.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $8,487,000 | 0.44% |
| Hawkeye Capital Management, LLC | 243,009 | $598,000 | 0.33% |
| Boxer Capital, LLC | 2,014,858 | $4,957,000 | 0.31% |
| Newtyn Management, LLC | 520,000 | $1,279,000 | 0.24% |
| Artal Group S.A. | 1,646,517 | $4,050,000 | 0.22% |
| DAFNA Capital Management LLC | 313,600 | $771,000 | 0.21% |
| RA Capital Management | 2,589,904 | $6,371,000 | 0.17% |
| Bellevue Group AG | 4,717,113 | $11,605,000 | 0.16% |
| MPM BioImpact LLC | 239,888 | $590,000 | 0.16% |
| K2 PRINCIPAL FUND, L.P. | 507,652 | $1,249,000 | 0.14% |